The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Deciphera
An open-label phase 1/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor.
 
Sreenivasa Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; deciphera; Kayothera; UpToDate
Research Funding - Acrivon Therapeutics (Inst); BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); NewBay Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Travel, Accommodations, Expenses - Alexion Pharmaceuticals
Other Relationship - WCG
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
Travel, Accommodations, Expenses - NewBay Pharma
 
Scott Okuno
Consulting or Advisory Role - Boehringer Ingelheim
 
Steven Attia
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; GlaxoSmithKline (Inst); Guardant Health; InhibRx (Inst); Intensity Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Noxopharm (Inst); PharmaMar (Inst); Philogen (Inst); Polaris (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Shanghai Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Alessandra Maleddu
Consulting or Advisory Role - Avoro Capital Advisors; Deciphera; SpringWorks Therapeutics
 
Jonathan Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Adam Burgoyne
Consulting or Advisory Role - AstraZeneca; Clinical Care Options; Deciphera; Eisai; Exelixis; Genentech/Roche
Speakers' Bureau - AstraZeneca; Deciphera
Research Funding - AstraZeneca (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Exelixis (Inst); InhibRx (Inst); Jiangsu Hengrui Medicine (Inst); Merck (Inst); Roche/Genentech (Inst); Signatera (Inst); Tvardi Therapeutics (Inst)
 
Vicki Keedy
Employment - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Deciphera
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); Shanghai Pharma (Inst); Tizona Therapeutics, Inc. (Inst); TRACON Pharma (Inst)
 
Vandy Black
Employment - Deciphera; FORMA Therapeutics; Novo Nordisk
Stock and Other Ownership Interests - Deciphera
Consulting or Advisory Role - University of Florida
Travel, Accommodations, Expenses - Deciphera
 
Bo King
No Relationships to Disclose
 
Anna Papinska
Employment - BioCryst; Deciphera
Stock and Other Ownership Interests - BioCryst
 
Elma Feric Bojic
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Ying Yuan
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Frederic Reu
Employment - Deciphera
Leadership - Deciphera
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Matthew Sherman
Employment - Deciphera
Leadership - Deciphera; Pieris Pharmaceuticals
Stock and Other Ownership Interests - Deciphera
Patents, Royalties, Other Intellectual Property - Deciphera
 
Michael Gordon
Stock and Other Ownership Interests - Sphinx HS (previously CAREMISSION)
Consulting or Advisory Role - Deciphera; Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Biosciences (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); DynamiCure Biotechnology (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); ImaginAb (Inst); Merck Serono (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); OncoResponse (Inst); Pfizer (Inst); Pionyr (Inst); Plexxikon (Inst); Pyxis (Inst); Revolution Medicines (Inst); Riboscience (Inst); Shenzen Ionova (Inst); Sirnaomics (Inst); SQZ Biotech (Inst); Syndax (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Application Serial No.: PCT/US24/27766 Filing Date: May 3, 2024 Title: Planet atmosphere gases enwrapped into composite nanomaterials with medical treatment applications